Pilot study for comparison of reticulocyte-micronulei with lymphocyte-micronuclei in human biomonitoring

• Published in: Toxicology letters Vol. 156; no. 3; pp. 351 - 360
• Main Authors: Stopper, H., Hempel, K., Reiners, Chr, Vershenya, S., Lorenz, R., Vukicevic, V., Heidland, A., Grawe, J.
• Format: Journal Article
• Language: English
• Published: Shannon Elsevier Ireland Ltd 28.04.2005; Amsterdam Elsevier Science
• Subjects: Adult; Biological and medical sciences; Dialysis; DNA Damage; Female; Humans; Iodine Radioisotopes - adverse effects; Iodine Radioisotopes - therapeutic use; Lymphocytes - physiology; Lymphocytes - radiation effects; Male; Medical sciences; Micronuclei; Micronuclei, Chromosome-Defective - radiation effects; Micronucleus Tests - methods; Micronucleus Tests - standards; Pilot Projects; Radioiodine therapy (RIT); Renal Dialysis - adverse effects; Renal Dialysis - methods; Reticulocytes; Reticulocytes - physiology; Reticulocytes - radiation effects; Toxicology; Reticulocytes; Dialysis; Radioiodine therapy (RIT); Micronuclei; Human; Treatment; Micronucleus; Reticulocyte; Lymphocyte; Comparative study; Biological monitoring
• ISSN: 0378-4274; 1879-3169
• DOI: 10.1016/j.toxlet.2004.12.007

Biomonitoring tries to determine the consequences for humans of exposures to environmental or pharmaceutical agents. Different end points have been employed to assess the burden of genomic damage. This is the first report comparing a recently introduced new end point, the reticulocyte-micronuclei analyzed by flow cytometry with the widely used lymphocyte-micronucleus assay, applied to two exposure scenarios leading to enhanced genomic damage. Radioiodine therapy was chosen to represent a short time exposure and hemodialysis treatment in end-stage renal failure was chosen to represent a chronic exposure. The results show that iodine radiation induced measurable genomic damage in the lymphocyte-micronucleus assay as well as in the reticulocyte-micronucleus test. Of two groups of patients under hemodialysis treatment, a reduced genomic damage was found with the lymphocyte-micronucleus test, but not with the reticulocyte-micronucleus test in the group undergoing daily hemodialysis, which removes uremic toxins more efficiently as compared to conventional hemodialysis, the treatment applied in the other group. The limited life-span of reticulocytes may make them less suitable for accumulation of chronic low level damage than lymphocytes. In conclusion, the lymphocyte-micronucleus test may be applicable to more exposure situations (including low chronic exposure), but the reticulocyte-micronucleus assay may be easier to perform in a clinical setting. The latter reflects a more rapid reduction of genomic damage after an acute exposure.